PRIMARY OPEN ANGLE GLAUCOMA (POAG)
Clinical trials for PRIMARY OPEN ANGLE GLAUCOMA (POAG) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY OPEN ANGLE GLAUCOMA (POAG) trials appear
Sign up with your email to follow new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New glaucoma treatment aims to protect vision by boosting eye cell energy
Disease control CompletedThis study tested whether adding a medication called Mexidol to standard glaucoma treatment could help protect the optic nerve and slow vision loss. It involved 80 people with advanced glaucoma whose eye pressure was already under control. Researchers measured changes in the heal…
Matched conditions: PRIMARY OPEN ANGLE GLAUCOMA (POAG)
Phase: PHASE4 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New drug trial aims to slow vision loss from glaucoma
Disease control CompletedThis study tested different doses of an investigational drug called Mexidol to see if it could help control primary open-angle glaucoma, a leading cause of irreversible vision loss. It involved 102 patients with moderate to severe glaucoma who were already managing their eye pres…
Matched conditions: PRIMARY OPEN ANGLE GLAUCOMA (POAG)
Phase: PHASE2 • Sponsor: Pharmasoft • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC